7Natural health products and cancer chemotherapy and radiation therapy

Oncology Reviews

Volumn 1, Issue 4, 2008, Pages 233-242

  Oneschuk, Doreen ^a,b   Younus, Jawaid ^c  

^a GREY NUNS COMMUNITY HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Cancer; Chemotherapy; Herbs; Natural health products; Radiation therapy

Indexed keywords

EID: 74849134146     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-008-0028-6     Document Type: Review

References (86)

1. Ernst E, Cassileth BR (1998) The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 83:777-782 (Pubitemid 28387704)
2. National Health Product Directorate (NHPD) Natural Health Products. 2006 Ottawa: Health Canada
3. Seely D, Stempak D, Baruchel S (2007) A strategy for controlling potential interactions between natural health products and chemotherapy. A review in pediatric oncology. J Pediatr Hematol Oncol 29:32-47 (Pubitemid 46143024)
4. Ganz PA, Desmond KA, Leedham B, et al (2002) Quality of life in long-term disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94:39-49 (Pubitemid 34082842)
5. Bernstein HJ, Grasso T (2001) Prevalence of complementary and alternative medicine use in cancer patients. Oncology 15:1267-1272 (Pubitemid 33739237)
6. Werneke U, Earl J, Seydel C et al (2004) Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 90:408-413 (Pubitemid 38250637)
7. Sparreboom A, Cox MC, Acharya MR, Figg WD (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22:2489-2503 (Pubitemid 41115408)
8. Blumenthal RS, Becker DM, Yanek LR et al (2003) Detecting occult coronary disease in a high-risk asymptomatic population. Circulation 107:702-707 (Pubitemid 36222597)
9. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and implications for oncology. J Clin Oncol 18:2505-2514 (Pubitemid 30432515)
10. Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA (2004) Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 22:4810-4815
11. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733-1739 (Pubitemid 29252602)
12. Vapiwala N, Mick R, DeNittis A, Hampshire M, Metz J (2005) Initiation of complementary and alternative medical therapies (CAM) by cancer patients during radiation therapy (RT). Proc Am Soc Ther Radiat Oncol 63(Suppl): S451
13. Gupta D, Lis CG, Birdsall TC, Grutsch JF (2005) The use of dietary supplements in a community hospital comprehensive center: implications for conventional cancer care. Support Care Cancer 13:912-919 (Pubitemid 41502251)
14. McCune JA, Hatfield AJ, Blackburn A, Leith PO et al (2004) Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 12:454-462 (Pubitemid 38797102)
15. Cai Y, Luo Z, Sung M, Corke H (2004) Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. Life Sciences 74:2157-2184 (Pubitemid 38210440)
16. Lopaczynski W, Zeisel SH (2001) Antioxidants, programmed cell death, and cancer. Nutr Res 21:295-307 (Pubitemid 32222277)
17. Seifried HG, McDonald SS, Anderson DE et al (2003) The antioxidant conundrum in cancer. Cancer Res 63:4295-4298 (Pubitemid 36957895)
18. Drisko JA, Chapman J, Hunter VJ (2003) The use of antioxidants during chemotherapy. Gynecol Oncol 88:434-439
19. Conklin KA (2000) Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutrition and Cancer 37:1-18 (Pubitemid 30650661)
20. Conklin KA (2004) Chemotherapy-Associated Oxidative Stress: Impact on Chemotherapeutic Effectiveness. Integr Cancer Ther 3:294-300 (Pubitemid 39552423)
21. Conklin KA (2004) cancer chemotherapy and antioxidants. J Nutrition 134:3201S-3204S (Pubitemid 39470116)
22. Lamson DW, Brignall MS (1999) Antioxidants in cancer therapy: their actions and interactions with oncologic therapies. Altern Med Rev 4:304-329 (Pubitemid 29526338)
23. Lamson Dw, Brignall MS (2000) Antioxidants and cancer therapy II: quick reference guide. Altern Med Rev 5:152-163 (Pubitemid 30226471)
24. Block KI (2004) Antioxidants and Cancer Therapy: Furthering the Debate. Integr Cancer Ther 3:342-348 (Pubitemid 39552428)
25. Lenzahofer R, Ganzinger U, Rameis H, Moser K (1983) Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment. J Cancer Res Clin Oncol 106:143-147 (Pubitemid 14227094)
26. Ladas EJ, Jacobson JS, Kennedy DD et al (2004) Antioxidants and cancer therapy: a systematic review. J Clin Oncol 22:517-528 (Pubitemid 41079781)
27. Prasad KN, Cole WC, Kumar B, Prasad KC (2001) Scientific Rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. J Am Coll Nutrition 20:450S-463S (Pubitemid 32948029)
28. Simone CBII, Simone NL, Simone V, Simone CB (2007) Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, Part 1. Alternative Therapies 13:22-28 (Pubitemid 46110631)
29. Mandlekar S, Hong J-L, Kong AH (2006) Modulation of metabolic enzymes by dietary phytochemicals: a review of mechanisms underlying beneficial versus unfavorable effects. Current Drug Metabolism 7:661-675
30. Epstein KR (2003) The role of carotenoids on the risk of lung cancer. Semin Oncol 30:86-93 (Pubitemid 36254678)
31. Vershinin AO, Kamnev AN (1996) [Mechanisms of antitumor activity of carotenoids]. Vopr Med Khim 42:275-277
32. Gordializa M, Castro MA, del Corral JM, Feliciano AS (2000) Antitumor properties of podophyllotoxin and related compounds, Curr Pharm Des 6:1811-1839
33. Lai PK, Roy J (2004) Antimicrobial and chemopreventive properties of herbs and spices. Current Medicinal Chemistry 11:1451-1460 (Pubitemid 38735789)
34. Mizutani K, Ikeda K, Kawai Y, Yamori Y (2001) Protective effect of resveratrol on oxidative damage in male and female stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 28:55-59 (Pubitemid 32039558)
35. Timothy TO, Janice FW, Carl LK (2003) Chronic consumption of flavanol and procyanindin-rich diet is associated with reduced levels of 8-hydroxy-2-deoxyguanosine in rat testes. J Nutr Biochem 14:104-110
36. Lee SH, Jung BH, Kim SY, Chung BC (2004) Determination of phytoestrogens in traditional medicinal herbs using gas chromatography-mass spectrometry. J Nutritional Biochem 15:452-460 (Pubitemid 39118491)
37. Dixon-Shanies D, Shaikh N (1999) Growth inhibition of human breast cancer cells by herbs and phytoestrogens. Oncol Rep 6:1383-1387
38. Yang CS, Landau JM, Huang MT, Newmark HL (2001) Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutrition 21:381-406 (Pubitemid 32695277)
39. Lau CBS, Ho CY, Kim CF et al (2004) Cytotoxic activities of Coriolus versicolor (Yunzhi) extract on human leukemia and lymphoma cells by induction of apoptosis. Life Sciences 75:797-808 (Pubitemid 38737418)
40. Yip ECH, Chan ASL, Pang H et al (2006) Protocatechiuc acid induces cell death in HepG2 hepatocellular carcinoma cells through a c-Jun-N-terminal kinase-dependent mechanism. Cell Biol Toxicol 22:293-302 (Pubitemid 44050819)
41. Peng P-L, Hsieh Y-S, Wang C-J et al (2006) Inhibitory effect of berberine on the invasion of the human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2, Toxicol Applied Pharmacol 214:8-15 (Pubitemid 43867664)
42. Jiang C, Lee H-J, Li G-X et al (2006) Potent antiandrogen and androgen receptor activities of an angelica gigascontaining herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res 66:453-463 (Pubitemid 43166054)
43. Chen X, Hu Z-P, Yang X-X et al (2006) Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. Int Immunopharmacol 6:499-508 (Pubitemid 43124011)
44. Amiroghofran Z, Balunanii M, Azadmehr A, Javidnia K (2006) Induction of apoptosis in leukemia cell lines by Linum persicum and Euphorbia cheiradenia J Cancer Res Clin Oncolo 132:427-432
45. Powell CB, Fung P, Jackson J et al (2003) Aqueous extract of herba Scutellaria barbatae, a chinese herb used for ovarian cancer, induces apoptosis of ovarian cancer cell lines. Gyneocol Oncol 91:332-340 (Pubitemid 37346328)
46. Ko S-G, Koh S-H, Jun C-Y et al (2004) Induction of Apoptosis by Saussurea lappa and Pharbitis nil on AGS Gastric Cancer Cells. Biol Pharm Bull 27:1604-1610 (Pubitemid 41701648)
47. Lee H-J, Lee E-O, Rhee Y-H et al (2006) An oriental herbal cocktail, kami-kae-kyuk-tang, exerts anti-cancer activities by targeting angiogenesis, apoptosis, and metastasis. Carcinogenesis 27:2455-2463 (Pubitemid 44884103)
48. Patel NM, Nozaki S, Shortle NH et al (2000) Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19:4159-4169
49. McCulloch M, See C, Shu X-J et al (2006) Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 24:419-430 (Pubitemid 46655594)
50. Mok TSK, Yeo W, Johnson PJ et al (2007) A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapyinduced toxicity. Ann Oncol 18:768-774 (Pubitemid 46523283)
51. Taixiang W, Wei X, Yang X, Zhiyu C (2007) Medicinal herbs for esophageal cancer (Review). Cochrane Database of Systematic Reviews, Issue 1
52. Taixiang W, Munro AJ, Guanjian L (2005) Chinese medical herbs for chemotherapy side effects in colorectal cancer patients (Review). Cochrane Database of Systematic Reviews, Issue 1
53. Shu Z, McCulloch M, Xiao H et al (2005) Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Integrative Cancer Therapies 4:219-229 (Pubitemid 41153748)
54. Rekha PS, Kuttan G, Kuttan R (2001) Effect of brahma rasayana on antioxidant system after radiation. Indian J Exp Biol 39:1173-1175 (Pubitemid 33066228)
55. Puri HS (2003) Rasayana-Ayurvedic herbs for longevity and rejuvenation. Taylor and Francis, London
56. Govindarajan R, Vijayakumar M, Pushpangadan P (2005) Antioxidant approach to disease management and the role of 'Rasayana' herbs of Ayurveda. J Ethnopharmacol 99:165-178 (Pubitemid 40724391)
57. Pal D, Mitra AK (2006) MDR and CYP3A4-mediated drug-herbal interactions. Life Sciences 78:2131-2145
58. Mandlekar S, Hong J-L, Kong AH (2006) Modulation of metabolic enzymes by dietary phytochemicals of mechanisms underlying beneficial versus unfavorable effects. Current Drug Metabolism 7:661-675
59. Evans AM (2000) Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit 22:131-136 (Pubitemid 30083114)
60. Ioannides C (2002) Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32:451-478 (Pubitemid 34743619)
61. Wilkinson GR (1997) The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev 27:129-159 (Pubitemid 27417870)
62. Block KI, Gyllenhaal C (2002) Clinical corner-herb-drug interactions in cancer chemotherapy: theoretical concerns regarding drug metabolizing enzymes. Integrative Cancer Therapies 1:83-89 (Pubitemid 37101542)
63. Meijerman I, Jos H, Beijnnen, Jan HM Schellens (2006) Herb-drug interactions in oncology: focus on mechanisms of induction. The Oncologist 11:742-752 (Pubitemid 44157562)
64. Hardman JG, Limbird LE, Molinoff PB et al (1996) Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th Ed. McGraw Hill, New York
65. Watkins PB, Wrighton SA, Schuetz EG et al (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal muscosa of rats and man. J Clin Invest 80:1029-1036 (Pubitemid 18075638)
66. Guengerich FP, Martin MV, Beaune PH et al (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060 (Pubitemid 17204301)
67. Parkinson A (1996) An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 24:48-57
68. Chen CJ, Chin JE, Ueda K et al (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrugresistant human cells. 47:381-389
69. Leslie EM, Deeley RG, Cole SP (2001) Toxicological relevance of the multidrug resistance protein 1 MRP1 (ABCC1) and related transporters. Toxicology 167:3-23 (Pubitemid 32830943)
70. Weinstein RS, Kuszak JR, Kluskens LF, Coon JS (1990) P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 21:34-48 (Pubitemid 20042403)
71. Ambudkar SV, Dey S, Hrycyna CA et al (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398 (Pubitemid 29222564)
72. Lin JH, Yamazaki M (2003) Role of Pglycoprotein in pharmacokinetics: clinical implications Clin Pharmacokinet 42:59-98
73. Yu DK (1999) The contribution of Pglycoprotein to pharmacokinetic drugdrug interactions J Clin Pharmacol 39:1203-1211 (Pubitemid 30644000)
74. Cole SP, Bhardwaj G, Gerlach JH et al (1992) Overexpression of a transporter gene in multi-drug-resistant human lung cancer cell line. Science 258: 1850-1654
75. Deeley RG, Cole SP (1997) Function, evolution, and structure of multidrug resistance protein (MRP). Semin Cancer Biol 8:193-204 (Pubitemid 28041016)
76. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:3385-3427
77. Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931-959 (Pubitemid 32652819)
78. Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71:537-592 (Pubitemid 34800230)
79. Schinkel AH, Jonker HW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29 (Pubitemid 36078452)
80. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD (2003) Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Update 6:71-84 (Pubitemid 36565766)
81. Blumberg B, Sabbagh W Jr, Juguilon H et al (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195-3205 (Pubitemid 28496264)
82. Mathijsen RH, Verweij J, de Bruin P et al (2002) Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 94:1247-1249 (Pubitemid 34993875)
83. Frye RF, Fitzgerald SM, Lagattuta TF et al (2004) Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76:323-239
84. Smith P, Bullock JM, Booker BM et al (2004) The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 24:1508-1514 (Pubitemid 39426346)
85. Komoroski BJ, Parise RA, Egorin MJ et al (2005) Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin Cancer Res 11:6972-6979 (Pubitemid 41428756)
86. Tabb MM, Kholodovych V, Grun F et al (2004) Highly chlorinated PCBs inhibit the human xenobiotic response mediated by the steroid and xenobiotic receptor (SXR). Environ Health Perspect 112:163-169 (Pubitemid 38195824)